225 related articles for article (PubMed ID: 20832103)
21. Benefit from exemestane as extended adjuvant therapy after 5 years of adjuvant tamoxifen: intention-to-treat analysis of the National Surgical Adjuvant Breast And Bowel Project B-33 trial.
Mamounas EP; Jeong JH; Wickerham DL; Smith RE; Ganz PA; Land SR; Eisen A; Fehrenbacher L; Farrar WB; Atkins JN; Pajon ER; Vogel VG; Kroener JF; Hutchins LF; Robidoux A; Hoehn JL; Ingle JN; Geyer CE; Costantino JP; Wolmark N
J Clin Oncol; 2008 Apr; 26(12):1965-71. PubMed ID: 18332472
[TBL] [Abstract][Full Text] [Related]
22. Endometrial evaluation in postmenopausal breast cancer patients receiving tamoxifen: an ultrasound, color flow Doppler, hysteroscopic and histological study.
Exacoustos C; Zupi E; Cangi B; Chiaretti M; Arduini D; Romanini C
Ultrasound Obstet Gynecol; 1995 Dec; 6(6):435-42. PubMed ID: 8903921
[TBL] [Abstract][Full Text] [Related]
23. Microwave endometrial ablation for endometrial protection in women with breast cancer on adjuvant tamoxifen.
Zhu Y; Yang J
J Obstet Gynaecol Res; 2013 Sep; 39(9):1411-4. PubMed ID: 23815697
[TBL] [Abstract][Full Text] [Related]
24. Abnormalities detected on transvaginal ultrasonography in tamoxifen-treated postmenopausal breast cancer patients may represent endometrial cystic atrophy.
McGonigle KF; Shaw SL; Vasilev SA; Odom-Maryon T; Roy S; Simpson JF
Am J Obstet Gynecol; 1998 Jun; 178(6):1145-50. PubMed ID: 9662294
[TBL] [Abstract][Full Text] [Related]
25. Aromatase inhibitors reverse tamoxifen induced endometrial ultrasonographic changes in postmenopausal breast cancer patients.
Markovitch O; Tepper R; Fishman A; Aviram R; Cohen I
Breast Cancer Res Treat; 2007 Jan; 101(2):185-90. PubMed ID: 16897434
[TBL] [Abstract][Full Text] [Related]
26. Prospective longitudinal study of ultrasound screening for endometrial abnormalities in women with breast cancer receiving tamoxifen.
Fung MF; Reid A; Faught W; Le T; Chenier C; Verma S; Brydon E; Fung KF
Gynecol Oncol; 2003 Oct; 91(1):154-9. PubMed ID: 14529676
[TBL] [Abstract][Full Text] [Related]
27. The value of transvaginal ultrasonography in the prediction of endometrial pathologies in asymptomatic postmenopausal breast cancer tamoxifen-treated patients.
Markovitch O; Tepper R; Fishman A; Shapira J; Aviram R; Cohen I
Gynecol Oncol; 2004 Dec; 95(3):456-62. PubMed ID: 15581946
[TBL] [Abstract][Full Text] [Related]
28. Intergroup Exemestane Study mature analysis: overall survival data.
Jassem J;
Anticancer Drugs; 2008 Feb; 19 Suppl 1():S3-7. PubMed ID: 18340242
[TBL] [Abstract][Full Text] [Related]
29. Endometrial thickness and ovarian cysts as measured by ultrasound in asymptomatic postmenopausal breast cancer patients on various adjuvant treatments including tamoxifen.
Lindahl B; Andolf E; Ingvar C; Liedman R; Ranstam J; Willén R
Anticancer Res; 1997; 17(5B):3821-4. PubMed ID: 9427787
[TBL] [Abstract][Full Text] [Related]
30. Evaluation of endometrial thickness in hormone receptor positive early stage breast cancer postmenopausal women switching from adjuvant tamoxifen treatment to anastrozole.
Valenzano Menada M; Costantini S; Moioli M; Bogliolo S; Papadia A; Ferrero S; Dugnani MC
Breast; 2008 Dec; 17(6):631-6. PubMed ID: 18606545
[TBL] [Abstract][Full Text] [Related]
31. The endometrium in asymptomatic breast cancer patients on tamoxifen: value of transvaginal ultrasonography with saline infusion and Doppler flow.
Develioğlu OH; Omak M; Bilgin T; Esmer A; Tüfekçi M
Gynecol Oncol; 2004 May; 93(2):328-35. PubMed ID: 15099941
[TBL] [Abstract][Full Text] [Related]
32. The effects on lipid serum levels of a 2-year adjuvant treatment with exemestane after tamoxifen in postmenopausal women with early breast cancer.
Montagnani A; Gonnelli S; Cadirni A; Caffarelli C; Del Santo K; Pieropan C; Campagna MS; Montomoli M; Petrioli R; Nuti R
Eur J Intern Med; 2008 Dec; 19(8):592-7. PubMed ID: 19046724
[TBL] [Abstract][Full Text] [Related]
33. Lipid changes in breast cancer patients on exemestane treatment: final results of the TEAM Greek substudy.
Markopoulos C; Polychronis A; Dafni U; Koukouras D; Zobolas V; Tzorakoleftherakis E; Xepapadakis G; Gogas H
Ann Oncol; 2009 Jan; 20(1):49-55. PubMed ID: 18678766
[TBL] [Abstract][Full Text] [Related]
34. Reducing the risk for breast cancer recurrence after completion of tamoxifen treatment in postmenopausal women.
Jahanzeb M
Clin Ther; 2007 Aug; 29(8):1535-47. PubMed ID: 17919537
[TBL] [Abstract][Full Text] [Related]
35. Discrepancy between ultrasonography and hysteroscopy and histology of endometrium in postmenopausal breast cancer patients using tamoxifen.
Mourits MJ; Van der Zee AG; Willemse PH; Ten Hoor KA; Hollema H; De Vries EG
Gynecol Oncol; 1999 Apr; 73(1):21-6. PubMed ID: 10094875
[TBL] [Abstract][Full Text] [Related]
36. Ultrasonographic measurement of endometrial changes following discontinuation of tamoxifen treatment in postmenopausal breast cancer patients.
Cohen I; Beyth Y; Azaria R; Flex D; Figer A; Tepper R
BJOG; 2000 Sep; 107(9):1083-7. PubMed ID: 11002949
[TBL] [Abstract][Full Text] [Related]
37. The ATAC adjuvant breast cancer trial in postmenopausal women: baseline endometrial subprotocol data.
Duffy S; Jackson TL; Lansdown M; Philips K; Wells M; Pollard S; Clack G; Cuzick J; Coibion M; Bianco AR
BJOG; 2003 Dec; 110(12):1099-106. PubMed ID: 14664881
[TBL] [Abstract][Full Text] [Related]
38. The effect of tamoxifen on the endometrium, serum lipids and hypothalamus pituitary axis in the postmenopausal breast cancer patients.
Kavak ZN; Binöz S; Ceyhan N; Pekin S
Acta Obstet Gynecol Scand; 2000 Jul; 79(7):604-7. PubMed ID: 10929963
[TBL] [Abstract][Full Text] [Related]
39. Quality of life in the intergroup exemestane study: a randomized trial of exemestane versus continued tamoxifen after 2 to 3 years of tamoxifen in postmenopausal women with primary breast cancer.
Fallowfield LJ; Bliss JM; Porter LS; Price MH; Snowdon CF; Jones SE; Coombes RC; Hall E
J Clin Oncol; 2006 Feb; 24(6):910-7. PubMed ID: 16484701
[TBL] [Abstract][Full Text] [Related]
40. Exemestane for primary prevention of breast cancer in postmenopausal women.
Zhang Y; Simondsen K; Kolesar JM
Am J Health Syst Pharm; 2012 Aug; 69(16):1384-8. PubMed ID: 22855103
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
